Claims
- 1. A compound of formula I
- 2. The compound of claim 1 wherein R2 is benzyl or substituted benzyl.
- 3. The compound of claim 1 wherein R2 is benzyl or substituted benzyl.
- 4. A compound selected from the group consisting of
N-hydroxy-N′-naphthalen-1-ylmethyl-terephthalamide; 4-(4-benzhydryl-piperazine-1-carbonyl)-N-hydroxy-benzamide; N-hydroxy-N′-pyridin-3-ylmethyl-terephthalamide; N-benzyl-N′-hydroxy-terephthalamide; N-cyclohexyl-N′-hydroxy-terephthalamide; N-cyclopropyl-N′-hydroxy-terephthalamide; N-hexyl-N′-hydroxy-terephthalamide; N-hydroxy-N′-(3-methyl-butyl)-terephthalamide; N-hydroxy-N′-phenethyl-terephthalamide; and N-hydroxy-N′-[2-(4-methoxy-phenyl)-ethyl]-terephthalamide.
- 5. A compound selected from the group consisting of
N-(3-chloro-benzyl)-N′-hydroxy-terephthalamide; N-hydroxy-N′-(2-methoxy-benzyl)-terephthalamide; N-(4-fluoro-benzyl)-N′-hydroxy-terephthalamide; N-hydroxy-N′-(1,2,3,4-tetrahydro-naphthalen-1-yl)-terephthalamide; N-hydroxy-N′-(4-trifluoromethyl-benzyl)-terephthalamide; N-(2,4-difluoro-benzyl)-N′-hydroxy-terephthalamide; N-hydroxy-N′-indan-1-yl-terephthalamide; N-benzo [1,3]dioxol-5-ylmethyl-N′-hydroxy-terephthalamide; N-hydroxy-4-(4-phenyl-piperazine-1-carbonyl)-benzamide; and N-(3,5-dimethyl-benzyl)-N′-hydroxy-terephthalamide.
- 6. A compound selected from the group consisting of
N-hydroxy-N′-(3-isopropoxy-propyl)-terephthalamide; 4-(4-acetyl-piperazine-1-carbonyl)-N-hydroxy-benzamide; N,N-dibutyl-N′-hydroxy-terephthalamide; 4-(4-benzyl-piperidine-1-carbonyl)-N-hydroxy-benzamide; N-hydroxy-N′-[2-(1-methyl-pyrrolidin-2-yl)-ethyl]-terephthalamide; N-(2-ethoxy-benzyl)-N′-hydroxy-terephthalamide; N-(2-cyclohex-1-enyl-ethyl)-N′-hydroxy-terephthalamide; N-hydroxy-N′-(2-morpholin-4-yl-ethyl) terephthalamide; N-hydroxy-N′-(2-methylsulfanyl-ethyl)-terephthalamide; and N-hydroxy-N′-(tetrahydro-furan-2-ylmethyl)-terephthalamide.
- 7. A process of manufacturing a compound of formula I comprising
reacting a compound of formula III 10 with an amine of the formula HNR1R2 in the presence of an activating agent, to give a compound of formula II 11 reacting the compound of formula II with hydroxylamine in the presence of a suitable base, wherein 12 is a phenyl ring that may be unsubstituted or substituted by 1, 2 or 3 substituents independently selected from halogen, a C1-4-alkyl-, trifluoromethyl-, hydroxy-, C1-4-alkoxy-, nitro-, amino-, C1-4-alkylamino-, di[C1-4-alkyl]-amino-, C1-4-alkanoylamino, a C1-3-alkylenedioxy-group or an acyl group; R1 and R2 are each independently selected from hydrogen, a branched or unbranched C1-14-alkyl group that
may be unsubstituted or substituted with 1 or more substituents independently selected from halogen, hydroxy-, nitro-, an amino group, a carbocyclic group or a heterocyclic group, and wherein at a chain length of longer than 2 carbon atoms, one or more non adjacent atoms may be replaced by oxygen, nitrogen or sulfur atoms, and wherein 2 atoms may be bound together by a double or triple bond, a carbocyclic group, and a heterocyclic group, or alternatively, the group —NR1R2 forms a 3-6 membered ring that may contain additional heteroatoms independently selected from nitrogen, oxygen and sulfur, said ring optionally being annulated to a carbocyclic ring or a heterocyclic ring, and said —NR1R2 ring being unsubstituted or optionally substituted by 1, 2, or 3 substituents independently selected from a halogen atom, an C1-4-alkyl-, trifluoromethyl-, hydroxy-, C1-4-alkoxy-, aryl-, hetaryl-, arylalkyl, arylalkyloxy-, aryloxy, C1-3-alkylenedioxy-, nitro-, amino-, C1-4-alkylamino-, di[C1-4-alkyl]amino-, C1-4-alkanoylamino- or an acyl-group; and R3 is C1-4-alkyl.
- 8. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 and a pharmaceutically acceptable carrier or excipient.
- 9. A method of treating breast, lung, colon, rectal, stomach, prostate, bladder, pancreas or ovarian cancer comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound of claim 1.
- 10. A compound of formula
Priority Claims (1)
Number |
Date |
Country |
Kind |
01114496.1 |
Jun 2001 |
EP |
|
PRIORITY TO RELATED APPLICATIONS
[0001] This application is a Division of Ser. No. 10/167,677, filed Jun. 11, 2002, which is now pending.
Divisions (1)
|
Number |
Date |
Country |
Parent |
10167677 |
Jun 2002 |
US |
Child |
10847166 |
May 2004 |
US |